Recruiting now

Trials using treatments to slow, stop or reverse Parkinson’s

The Cure Parkinson's Trust manage and facilitate an innovative research programme called Linked Clinical Trials with the sole aim of bringing forward treatments that biochemically show the potential to slow, stop or reverse Parkinson's. Each year around 25 compounds are evaluated and prioritised by some of the world's leading Parkinson's experts to decide which drugs should be brought forward into trial. More details of the programme can be found here. The first being brought forward into trial are Deferiprone and Simvastatin. You can also find factsheets about the Deferiprone trial and the Simvastatin trial on The Cure Parkinson's Trust website. A study to examine the safety and efficacy of the drug Liraglutide is also underway. More information here available on The Cure Parkinson's Trust website here.

If you are interested in taking part in other trials you can register with Fox Trial Finder. Fox Trial Finder was created by the Michael J. Fox Foundation to help increase the numbers of people taking part in trials to accelerate the Parkinson's drug development process. This includes both people living with Parkinson’s and ‘control’ participants who do not have Parkinson’s. There is also more general information about trials.

The NHS National Institute for Health Research provide detailed information and useful resources and links about clinical trials and what to expect. NHS Choices also provide an overview of taking part in a trial, what to expect and links to other useful resources.

Linked Clinical Trials – new treatments to slow, stop and reverse Parkinson’s

RELATED ITEMS

  • Rallying to the challenge 2014 focused on how people with Parkinson’s (PwP) can strongly influence the effectiveness of clinical trials. Clinical trials are essential in assessing how effective or safe treatments are as well as advancing a greater understanding about a condition. The process of medicine development from test-tube to…
  • What is Rallying to the Challenge?Rallying to the Challenge, hosted by  The Cure Parkinson’s Trust and Parkinson’s Movement, brings together people with Parkinson’s and advocates from around the world to devise ways to positively impact clinical trials and research.This conference has one simple aim – to involve people living with…
  • Dr David Devos is leading Europe-wide consortia of neurologists and Parkinson’s specialists to secure funding from the EU’s Horizon 2020 programme to run a clinical trial through 28 centres across Europe to understand the efficacy of Deferiprone, an iron-chelator in the treatment of people with Parkinson’s. 'The Cure Parkinson’s Trust…
  • At our patient advocate Rallying to the Challenge Meeting in 2014 it was unanimously agreed in the value of developing a clinical trials charter to significantly improve communication between those taking part in trials and those running clinical trials. The Charter was developed by people living with Parkinson's and clinicians…
  • On the 17th October, the New Scientist reported exciting results from a six month study of twelve patients with Parkinson’s or Lewy Body Dementia taking an expensive cancer drug called nilotinib.  The article announced that scientists at Georgetown University Medical Centre in Washington had seen 'fast improvement' in the volunteers…